Patritumab
Cat. No.: IBDI-432056
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.
Product Details
| Target |
EGFR | Akt | ERK | PARP | Survivin |
| Appearance |
Liquid |
| Synonyms |
Human Anti-ERBB3 Recombinant Antibody |
| SMILES |
[Patritumab] |
| Purity |
98.94% |
Storage & Handling
| Shipping |
Shipping with dry ice. |
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
